Salvianti Francesca, Giuliani Corinna, Petrone Luisa, Mancini Irene, Vezzosi Vania, Pupilli Cinzia, Pinzani Pamela
Department of Experimental and Clinical Biomedical Sciences, Molecular and Clinical Biochemistry Unit, Careggi Hospital and University of Florence, 50134 Florence, Italy.
Department of Clinical, Experimental and Biomedical Sciences, Endocrinology Unit, Careggi Hospital and University of Florence, 50134 Florence, Italy.
Int J Mol Sci. 2017 Jun 24;18(7):1350. doi: 10.3390/ijms18071350.
Cell-free DNA (cfDNA) quantity and quality in plasma has been investigated as a non-invasive biomarker in cancer. Previous studies have demonstrated increased cfDNA amount and length in different types of cancer with respect to healthy controls. The present study aims to test the hypothesis that the presence of longer DNA strands circulating in plasma can be considered a biomarker for tumor presence in thyroid cancer. We adopted a quantitative real-time PCR (qPCR) approach based on the quantification of two amplicons of different length (67 and 180 bp respectively) to evaluate the integrity index 180/67. Cell-free DNA quantity and integrity were higher in patients affected by nodular thyroid diseases than in healthy controls. Importantly, cfDNA integrity index was higher in patients with cytological diagnosis of thyroid carcinoma (Thy4/Thy5) than in subjects with benign nodules (Thy2). Therefore, cfDNA integrity index 180/67 is a suitable parameter for monitoring cfDNA fragmentation in thyroid cancer patients and a promising circulating biomarker in the diagnosis of thyroid nodules.
血浆中游离DNA(cfDNA)的数量和质量已作为癌症的一种非侵入性生物标志物进行了研究。先前的研究表明,与健康对照相比,不同类型癌症中的cfDNA数量和长度有所增加。本研究旨在检验以下假设:血浆中循环的较长DNA链的存在可被视为甲状腺癌中肿瘤存在的生物标志物。我们采用了基于定量两种不同长度扩增子(分别为67和180 bp)的定量实时PCR(qPCR)方法来评估完整性指数180/67。结节性甲状腺疾病患者的cfDNA数量和完整性高于健康对照。重要的是,甲状腺癌细胞学诊断为(Thy4/Thy5)的患者的cfDNA完整性指数高于良性结节(Thy2)的患者。因此,cfDNA完整性指数180/67是监测甲状腺癌患者cfDNA片段化的合适参数,也是诊断甲状腺结节的一种有前景的循环生物标志物。